Literature DB >> 14730268

Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis.

Todd C Carpenter1, Kurt R Stenmark.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) causes the highest rate of severe respiratory infections and mortality in infants and children worldwide. Preterm infants with underlying chronic lung disease (CLD), including bronchopulmonary dysplasia (BPD), are among those at high risk for severe morbidity, long term sequelae and mortality postinfection. The definition of CLD/BPD has evolved and is currently described as a disease of restricted lung development (i.e. impaired alveolar and pulmonary vascular development). This article describes potential mechanisms by which RSV infection causes respiratory failure in the infant with BPD. METHODS AND
RESULTS: The opinions expressed in this article are based on a review of recent investigations into the mechanisms through which RSV infections could cause excessive pulmonary edema formation and subsequent respiratory failure in the infant with CLD. Although alveolar overinflation and atelectasis are well-described patterns of RSV-induced respiratory illness in this infant population, the finding of pulmonary edema is a complex, multifactorial process that is less well understood. Experimental evidence suggests that RSV infection in infants with CLD/BPD not only causes increases in pulmonary vascular reactivity but also precipitates pulmonary edema formation via multiple mechanisms (e.g. nonuniform elevations in pulmonary artery pressure, endothelial injury, alveolar epithelial damage and impairments of native alveolar liquid clearance mechanisms).
CONCLUSIONS: Novel therapies for managing RSV-induced respiratory failure in the infant with CLD/BPD must consider factors responsible for the substantial pulmonary vascular component of this illness.

Entities:  

Mesh:

Year:  2004        PMID: 14730268     DOI: 10.1097/01.inf.0000108191.13799.09

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Inhibiting NF-κB in the developing lung disrupts angiogenesis and alveolarization.

Authors:  Cristiana Iosef; Tero-Pekka Alastalo; Yanli Hou; Chihhsin Chen; Eloa S Adams; Shu-Chen Lyu; David N Cornfield; Cristina M Alvira
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-24       Impact factor: 5.464

2.  Health Care and Societal Costs of Bronchopulmonary Dysplasia.

Authors:  Wannasiri Lapcharoensap; Henry C Lee; Amy Nyberg; Dmitry Dukhovny
Journal:  Neoreviews       Date:  2018-04

3.  New mouse model of pulmonary hypertension induced by respiratory syncytial virus bronchiolitis.

Authors:  Dai Kimura; Jordy Saravia; Sridhar Jaligama; Isabella McNamara; Luan D Vu; Ryan D Sullivan; Salvatore Mancarella; Dahui You; Stephania A Cormier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-15       Impact factor: 4.733

4.  Metyrapone alleviates deleterious effects of maternal food restriction on lung development and growth of rat offspring.

Authors:  David S Paek; Reiko Sakurai; Aditi Saraswat; Yishi Li; Omid Khorram; John S Torday; Virender K Rehan
Journal:  Reprod Sci       Date:  2014-06-10       Impact factor: 3.060

5.  Current pharmacologic approaches for prevention and treatment of bronchopulmonary dysplasia.

Authors:  Kristen Tropea; Helen Christou
Journal:  Int J Pediatr       Date:  2012-01-03

Review 6.  Looking ahead: where to next for animal models of bronchopulmonary dysplasia?

Authors:  Claudio Nardiello; Ivana Mižíková; Rory E Morty
Journal:  Cell Tissue Res       Date:  2016-12-05       Impact factor: 5.249

7.  Comparative two time-point proteome analysis of the plasma from preterm infants with and without bronchopulmonary dysplasia.

Authors:  Magdalena Zasada; Maciej Suski; Renata Bokiniec; Monika Szwarc-Duma; Maria Katarzyna Borszewska-Kornacka; Józef Madej; Beata Bujak-Giżycka; Anna Madetko-Talowska; Cecilie Revhaug; Lars O Baumbusch; Ola D Saugstad; Jacek Józef Pietrzyk; Przemko Kwinta
Journal:  Ital J Pediatr       Date:  2019-08-24       Impact factor: 2.638

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.